Loading...

Aquarius Surgical Technologies

OTCPK:AQQR.F
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AQQR.F
OTCPK
CA$7M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Aquarius Surgical Technologies Inc., through its subsidiary, Surgical Lasers Inc., engages in the development, sale, distribution, marketing, and exploitation of laser-driven technologies for use in surgical environments, principally in the field of urology. The last earnings update was 141 days ago. More info.


Add to Portfolio Compare Print
AQQR.F Share Price and Events
7 Day Returns
0%
OTCPK:AQQR.F
-0.4%
US Medical Equipment
-0.3%
US Market
1 Year Returns
-
OTCPK:AQQR.F
14.3%
US Medical Equipment
3.4%
US Market
AQQR.F Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Aquarius Surgical Technologies (AQQR.F) 0% 0% - - - -
US Medical Equipment -0.4% 3.1% 12.8% 14.3% 61.4% 101.8%
US Market -0.3% 2.9% 2.1% 3.4% 36.2% 41.3%
1 Year Return vs Industry and Market
  • No trading data on AQQR.F.
  • No trading data on AQQR.F.
Price Volatility
AQQR.F
Industry
5yr Volatility vs Market

AQQR.F Value

 Is Aquarius Surgical Technologies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Aquarius Surgical Technologies is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Aquarius Surgical Technologies has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Aquarius Surgical Technologies. This is due to cash flow or dividend data being unavailable. The share price is $0.3585.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Aquarius Surgical Technologies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Aquarius Surgical Technologies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:AQQR.F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in CAD CA$-0.31
CNSX:ASTI Share Price ** CNSX (2019-06-11) in CAD CA$0.35
United States of America Medical Equipment Industry PE Ratio Median Figure of 64 Publicly-Listed Medical Equipment Companies 40.96x
United States of America Market PE Ratio Median Figure of 3,083 Publicly-Listed Companies 17.88x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Aquarius Surgical Technologies.

OTCPK:AQQR.F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:ASTI Share Price ÷ EPS (both in CAD)

= 0.35 ÷ -0.31

-1.12x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aquarius Surgical Technologies is loss making, we can't compare its value to the US Medical Equipment industry average.
  • Aquarius Surgical Technologies is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Aquarius Surgical Technologies's expected growth come at a high price?
Raw Data
OTCPK:AQQR.F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.12x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Medical Equipment Industry PEG Ratio Median Figure of 55 Publicly-Listed Medical Equipment Companies 2.31x
United States of America Market PEG Ratio Median Figure of 2,124 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Aquarius Surgical Technologies, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Aquarius Surgical Technologies's assets?
Raw Data
OTCPK:AQQR.F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in CAD CA$-0.02
CNSX:ASTI Share Price * CNSX (2019-06-11) in CAD CA$0.35
United States of America Medical Equipment Industry PB Ratio Median Figure of 183 Publicly-Listed Medical Equipment Companies 4.41x
United States of America Market PB Ratio Median Figure of 5,245 Publicly-Listed Companies 1.8x
OTCPK:AQQR.F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:ASTI Share Price ÷ Book Value per Share (both in CAD)

= 0.35 ÷ -0.02

-19.61x

* Primary Listing of Aquarius Surgical Technologies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aquarius Surgical Technologies has negative assets, we can't compare the value of its assets to the US Medical Equipment industry average.

Next steps:

  1. Take a look at our analysis of AQQR.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Show me more potentially undervalued companies in the Medical Equipment industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Aquarius Surgical Technologies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Aquarius Surgical Technologies has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

AQQR.F Future Performance

 How is Aquarius Surgical Technologies expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Aquarius Surgical Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
21.9%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Aquarius Surgical Technologies expected to grow at an attractive rate?
  • Unable to compare Aquarius Surgical Technologies's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Aquarius Surgical Technologies's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Aquarius Surgical Technologies's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:AQQR.F Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.9%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.1%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:AQQR.F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:AQQR.F Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2018-12-31 1 -2 -6
2018-09-30 1 -2 -6
2018-06-30 1 -2 -6
2018-03-31 1 -2 -6
2017-12-31 1 -2 -2
2017-09-30 0 -1 -2
2017-06-30 0 -1 -1
2017-03-31 0 0 -1
2016-12-31 0 0
2016-09-30 0 0
2016-06-30 0 0
2016-03-31 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Aquarius Surgical Technologies is high growth as no earnings estimate data is available.
  • Unable to determine if Aquarius Surgical Technologies is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:AQQR.F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Aquarius Surgical Technologies Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:AQQR.F Past Financials Data
Date (Data in CAD Millions) EPS *
2018-12-31 -0.31
2018-09-30 -0.32
2018-06-30 -0.34
2018-03-31 -0.35
2017-12-31 -0.14
2017-09-30 -0.14
2017-06-30 -0.14
2017-03-31 -0.14
2016-12-31 0.02
2016-09-30 0.03
2016-06-30 0.03
2016-03-31 0.03

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Aquarius Surgical Technologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of AQQR.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Aquarius Surgical Technologies's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Aquarius Surgical Technologies's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Aquarius Surgical Technologies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Aquarius Surgical Technologies has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

AQQR.F Past Performance

  How has Aquarius Surgical Technologies performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Aquarius Surgical Technologies's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Aquarius Surgical Technologies does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Aquarius Surgical Technologies's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Aquarius Surgical Technologies's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Aquarius Surgical Technologies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Aquarius Surgical Technologies Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:AQQR.F Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.75 -5.91 1.57
2018-09-30 0.77 -6.06 1.55
2018-06-30 0.85 -6.20 1.56
2018-03-31 0.97 -6.25 1.54
2017-12-31 0.56 -2.22 1.84
2017-09-30 0.36 -1.71 1.48
2017-06-30 0.16 -1.30 1.19
2017-03-31 0.01 -0.88 0.84
2016-12-31 0.12 0.08
2016-09-30 0.14 0.06
2016-06-30 0.16 0.04
2016-03-31 0.16 0.04
2015-12-31 -0.04 0.05
2015-09-30 -0.03 0.04
2015-06-30 -0.02 0.03
2015-03-31 -0.03 0.03
2014-12-31 0.44 0.04
2014-09-30 0.42 0.04
2014-06-30 -0.05 0.46 -0.02
2014-03-31 0.41 0.05
2013-12-31 0.04 -0.11 0.11
2013-09-30 0.08 -0.16 0.17
2013-06-30 0.19 -0.27 0.32
2013-03-31 0.18 -0.29 0.34
2012-12-31 0.20 -0.34 0.35
2012-09-30 0.24 -0.33 0.35

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Aquarius Surgical Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Aquarius Surgical Technologies has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Aquarius Surgical Technologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Aquarius Surgical Technologies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Aquarius Surgical Technologies has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

AQQR.F Health

 How is Aquarius Surgical Technologies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Aquarius Surgical Technologies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Aquarius Surgical Technologies's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Aquarius Surgical Technologies has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Aquarius Surgical Technologies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Aquarius Surgical Technologies has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Aquarius Surgical Technologies Company Filings, last reported 6 months ago.

OTCPK:AQQR.F Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 -0.35 2.05 0.21
2018-09-30 -0.05 1.26 0.06
2018-06-30 0.25 1.06 0.17
2018-03-31 0.13 1.05 0.16
2017-12-31 4.97 0.98 0.16
2017-09-30 5.51 0.98 0.80
2017-06-30 4.59 1.70 0.63
2017-03-31 5.02 1.72 1.12
2016-12-31 -3.93 3.91 0.02
2016-09-30 -3.90 3.87 0.01
2016-06-30 -3.87 3.82 0.01
2016-03-31 -3.86 3.82 0.01
2015-12-31 -3.94 4.02 0.01
2015-09-30 -3.93 4.01 0.01
2015-06-30 -3.92 4.00 0.02
2015-03-31 -3.91 4.00 0.02
2014-12-31 -3.90 3.98 0.01
2014-09-30 -3.90 4.01 0.01
2014-06-30 -3.73 3.86 0.00
2014-03-31 -3.67 3.81 0.01
2013-12-31 -4.05 3.75 0.00
2013-09-30 -3.98 3.69 0.00
2013-06-30 -3.92 3.64 0.00
2013-03-31 -3.86 3.58 0.00
2012-12-31 -3.79 3.52
2012-09-30 -3.73 3.44
  • Aquarius Surgical Technologies has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Aquarius Surgical Technologies's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Aquarius Surgical Technologies has less than a year of cash runway based on current free cash flow.
  • Aquarius Surgical Technologies has less than a year of cash runway if free cash flow continues to grow at historical rates of 84.1% each year.
X
Financial health checks
We assess Aquarius Surgical Technologies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Aquarius Surgical Technologies has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

AQQR.F Dividends

 What is Aquarius Surgical Technologies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Aquarius Surgical Technologies dividends.
If you bought $2,000 of Aquarius Surgical Technologies shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Aquarius Surgical Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Aquarius Surgical Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:AQQR.F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2017 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Aquarius Surgical Technologies has not reported any payouts.
  • Unable to verify if Aquarius Surgical Technologies's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Aquarius Surgical Technologies's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Aquarius Surgical Technologies has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Aquarius Surgical Technologies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Aquarius Surgical Technologies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Aquarius Surgical Technologies has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

AQQR.F Management

 What is the CEO of Aquarius Surgical Technologies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
N. Van Nest
COMPENSATION CA$5,000
AGE 83
TENURE AS CEO 2.3 years
CEO Bio

Mr. N. Gary Van Nest, B.Comm., M.B.A. serves as the President of Sinalta Investments Ltd. Mr. Van Nest has over 38 years of extensive experience in the brokerage, merchant banking and investment management businesses. He has been the Chief Executive Officer of Aquarius Surgical Technologies Inc. since March 17, 2017 and serves as its Vice Chairman. He served as the President and Chief Executive Officer of Landmark Global Financial Corp. from January 1986 to March 2000. He served as the Chief Executive Officer of Alexander Energy Ltd. from October 1, 2011 to September 7, 2012. He served as the President of Wisener & Partners Co. Ltd. and Canadian Venture Capital Corporation. He served as the President and Chief Executive Officer of Triarch Corporation. He served as an Acting President at MedX Health Corp. since February 2008. He had been the Chairman of MedX Health Corp from December 2013 until September 24, 2018. He serves as Chairman of Elliott and Page Ltd.; Woodland Biofuels Inc. and MedX Health Corp. He serves as the Chairman of Woodland Biofuels Inc. and Encap Corporation. He served as the Chairman of MedX Health Corp from February 2008 to November 29, 2013. Mr. Van Nest served as the Chairman of Alexander Energy Ltd. from October 1, 2011 to September 7, 2012. He serves as a Director/Officer of several notable public and private companies, such as Cameco (formerly Eldorado Nuclear); Toromont Industries Ltd.; Pathfinder Beverages Ltd. and Noble China Ltd. He has been an Independent Director of MedX Health Corp since November 19, 2001. He has been a Director of Aquarius Surgical Technologies Inc. since 1989. He also remains a Director of several other public and private companies. He served as a Director of Alexander Energy Ltd. from October 16, 2009 to September 7, 2012. He served as an Independent Director of Landmark Global Financial Corporation from January 1986 to March 2000. He served as an Independent Director of CGF Funds Management Ltd. and Crown Hill Capital Corporation. He served as a Director of Viking International Petroleum, plc. until February 16, 2005; Citadel Diversified Management Ltd. and Citadel Fund Administrator. He also served as Chairman of the early fundraising efforts for Young People’s Theatre in Toronto. He was a Director of The Royal Canadian Geographical Society for five years. He was a Director and Supporter of the Hospice Calgary Society. Mr. Van Nest holds a Bachelor of Commerce degree from the University of Windsor and did postgraduate studies at McGill University and the University of Toronto.

CEO Compensation
  • Insufficient data for N. to compare compensation growth.
  • N.'s remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure of the Aquarius Surgical Technologies management team in years:

2.3
Average Tenure
  • The tenure for the Aquarius Surgical Technologies management team is about average.
Management Team

N. Van Nest

TITLE
CEO & Vice Chairman
COMPENSATION
CA$5K
AGE
83
TENURE
2.3 yrs

Gordon Willox

TITLE
President
COMPENSATION
CA$19K
TENURE
0.7 yrs

Lorne MacFarlane

TITLE
Chief Financial Officer
TENURE
9.7 yrs

Christopher Freeman

TITLE
Secretary
Board of Directors Tenure

Average tenure of the Aquarius Surgical Technologies board of directors in years:

2.3
Average Tenure
  • The average tenure for the Aquarius Surgical Technologies board of directors is less than 3 years, this suggests a new board.
Board of Directors

David Hennigar

TITLE
Chairman
AGE
79

N. Van Nest

TITLE
CEO & Vice Chairman
COMPENSATION
CA$5K
AGE
83

Gordon Willox

TITLE
President
COMPENSATION
CA$19K
TENURE
2.3 yrs

Robert Francis

TITLE
Director
TENURE
2.3 yrs

Stanley Swierzewski

TITLE
Director
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
07. Feb 19 Buy David Hennigar Individual 06. Feb 19 06. Feb 19 14,500 $0.23 $3,298
04. Feb 19 Buy David Hennigar Individual 01. Feb 19 01. Feb 19 1,000 $0.23 $229
01. Feb 19 Buy David Hennigar Individual 31. Jan 19 31. Jan 19 21,000 $0.23 $4,792
11. Jan 19 Buy David Hennigar Individual 10. Jan 19 10. Jan 19 4,500 $0.22 $985
09. Jan 19 Buy David Hennigar Individual 08. Jan 19 08. Jan 19 9,000 $0.23 $1,909
08. Jan 19 Buy David Hennigar Individual 07. Jan 19 07. Jan 19 9,000 $0.23 $2,029
04. Jan 19 Buy David Hennigar Individual 27. Dec 18 27. Dec 18 1,000 $0.22 $220
18. Nov 18 Buy David Hennigar Individual 15. Nov 18 15. Nov 18 1,000 $0.30 $303
14. Nov 18 Buy David Hennigar Individual 13. Sep 18 31. Oct 18 93,000 $0.32 $26,964
17. Sep 18 Buy Sinalta Investments Ltd Company 13. Sep 18 13. Sep 18 22,000 $0.27 $5,852
X
Management checks
We assess Aquarius Surgical Technologies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Aquarius Surgical Technologies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

AQQR.F News

Simply Wall St News

AQQR.F Company Info

Description

Aquarius Surgical Technologies Inc., through its subsidiary, Surgical Lasers Inc., engages in the development, sale, distribution, marketing, and exploitation of laser-driven technologies for use in surgical environments, principally in the field of urology. It provides minimally invasive medical laser systems and consumables for various medical disciplines, primarily for the treatment of benign prostatic hyperplasia. The company also offers solutions comprising clinical education, service, support, and maintenance. Its portable benign prostatic hyperplasia laser device supports all available fiber delivery systems. The company was formerly known as Aquarius Coatings Inc. Aquarius Surgical Technologies Inc. was incorporated in 1986 and is based in Toronto, Canada.

Details
Name: Aquarius Surgical Technologies Inc.
AQQR.F
Exchange: OTCPK
Founded: 1986
CA$5,637,869
21,083,539
Website: http://
Address: Aquarius Surgical Technologies Inc.
89 Scollard Street,
Toronto,
Ontario, M5R 1G4,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX ASTI Common Shares Canadian National Stock Exchange CA CAD 21. Jun 2017
OTCPK AQQR.F Common Shares Pink Sheets LLC US USD 21. Jun 2017
Number of employees
Current staff
Staff numbers
0
Aquarius Surgical Technologies employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/19 00:58
End of day share price update: 2019/06/11 00:00
Last earnings filing: 2019/02/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.